Recentin cediranib: Phase III data

AstraZeneca said it will not pursue further development of Recentin to treat recurrent glioblastoma based on top-line data from the

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE